enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Ionis Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Ionis_Pharmaceuticals

    Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...

  3. Eplontersen - Wikipedia

    en.wikipedia.org/wiki/Eplontersen

    Clinical trial number NCT04136184 for "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy" at ClinicalTrials.gov

  4. Ionis - Wikipedia

    en.wikipedia.org/wiki/IONIS

    IONIS Education Group; IONIS School of Technology and Management; Ionis Pharmaceuticals This page was last edited on 30 September 2018, at 19:02 (UTC). Text is ...

  5. IONIS Education Group - Wikipedia

    en.wikipedia.org/wiki/IONIS_Education_Group

    IONIS Education Group is a private, for-profit, higher education group in France. [6] It was created in 1980 [ 7 ] and by 2023 had more than 35,000 students and 100,000 alumni. [ 8 ] There are 29 further education colleges in the group.

  6. C. Frank Bennett - Wikipedia

    en.wikipedia.org/wiki/C._Frank_Bennett

    C. Frank Bennett is an American pharmacologist.Bennett is currently the Senior Vice President of Research and Neurology Franchise Leader at Ionis Pharmaceuticals. [1] He is a 2019 Breakthrough Prize winner in Life Sciences, which he shared with his collaborator Adrian R. Krainer for the development of an effective antisense oligonucleotide therapy for children with the neurodegenerative ...

  7. Tofersen - Wikipedia

    en.wikipedia.org/wiki/Tofersen

    Tofersen was developed by Ionis Pharmaceuticals and was licensed to, and co-developed by, Biogen. [7] [8]The effectiveness of tofersen was evaluated in a 28-week, randomized, double-blind, placebo-controlled clinical study in 147 participants with weakness attributable to amyotrophic lateral sclerosis and a superoxide dismutase 1 (SOD-1) mutation confirmed by a central laboratory. [2]

  8. IONIS-GCCRRx - Wikipedia

    en.wikipedia.org/wiki/IONIS-GCCRRx

    IONIS-GCCR Rx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. [ 1 ] [ 2 ] It has also been under investigation for the treatment of Cushing's syndrome , but no development has been reported. [ 1 ]

  9. IONIS School of Technology and Management - Wikipedia

    en.wikipedia.org/wiki/IONIS_School_of_Technology...

    IONIS School of Technology and Management (IONIS STM) is a French private graduate school, [1] part of the IONIS Education Group. The school offers instruction in information technology, computer science, energy, biotechnology and management. [2] It was established in 2009 in Ivry-sur-Seine. [3] [4]